Rare Mechanism of Acquired Resistance to Osimertinib in Korean Patients with EGFR-mutated Non-small Cell Lung Cancer
Cancer Research and Treatment. 2019;51(1):408-412 
Durable response to osimertinib in EGFR mutated T790M wildtype non-small cell lung cancer with leptomeningeal metastases: A case report
Lung Cancer. 2017;114:68-69
Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3 -mutation, localized transformation to EGFR -mutated SCLC, and acquired T790M EGFR -mutation
Lung Cancer. 2017;113:14-17
Challenges in the Management of EGFR-Mutated Non-Small Cell Lung Cancer Patients with Acquired Resistance to Tyrosine Kinase Inhibitors
Oncology. 2014;87(2):83-94
REBIOPSY IN NON-SMALL CELL LUNG CANCER PATIENTS WITH ACQUIRED RESISTANCE TO EGFR-TKI
Respirology. 2017;22:242-242
Osimertinib
Reactions Weekly. 2018;1721(1):226-226
Non-small cell lung cancer harboring a rare EGFR
L747P mutation showing intrinsic resistance to both gefitinib and osimertinib (AZD9291): A case report
Thoracic Cancer. 2018;9(6):745-749
Acquired EGFR L718V mutation mediates resistance to osimertinib in non-small cell lung cancer but retains sensitivity to afatinib
Lung Cancer. 2018;118:1-5
Osimertinib-induced Stevens-Johnson syndrome in a patient with EGFR T790M mutation-positive non-small cell lung cancer
Lung Cancer. 2019;129:110-111
Treating EGFR mutation resistance in non-small cell lung cancer – role of osimertinib
The Application of Clinical Genetics. 2017;Volume 10:49-56